In this study, we applied a novel, high-throughputglycoproteomicsplatform to the interrogation of serum glycoprotein isoforms withthe aim of finding clinically actionable, accurate biomarker panelsthat would allow for early, noninvasive recognition of NAFLD/NASHas well as monitoring the progression of fatty liver disorder to HCC. The gene discussed is ART4; the disease is hepatocellular carcinoma.